<SEC-DOCUMENT>0000320017-18-000078.txt : 20180621
<SEC-HEADER>0000320017-18-000078.hdr.sgml : 20180621
<ACCEPTANCE-DATETIME>20180621163030
ACCESSION NUMBER:		0000320017-18-000078
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20180620
FILED AS OF DATE:		20180621
DATE AS OF CHANGE:		20180621

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Talamo Joseph
		CENTRAL INDEX KEY:			0001524547

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		18912110

	MAIL ADDRESS:	
		STREET 1:		C/O NEOSTEM, INC.
		STREET 2:		420 LEXINGTON AVENUE, SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CALADRIUS BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-842-0100

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wf-form4_152961301286128.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2018-06-20</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000320017</issuerCik>
        <issuerName>CALADRIUS BIOSCIENCES, INC.</issuerName>
        <issuerTradingSymbol>CLBS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001524547</rptOwnerCik>
            <rptOwnerName>Talamo Joseph</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CALADRIUS BIOSCIENCES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>110 ALLEN ROAD, 2ND FLOOR</rptOwnerStreet2>
            <rptOwnerCity>BASKING RIDGE</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07920</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>SVP and CFO</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2018-06-20</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>13300</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>8.64</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>41617</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2018-06-20</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>6407</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>8.64</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>35210</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">Reflects 13,300 in performance rights, the criteria for which was satisfied on April 6, 2018 and which vested in full on June 20, 2018, when the shareholders voted to approve the new 2018 Equity Incentive Compensation Plan.</footnote>
        <footnote id="F2">Includes 9,975 shares of unvested restricted stock.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>Joseph Talamo, by: /s/Todd C. Girolamo, Esq., Attorney-in-Fact</signatureName>
        <signatureDate>2018-06-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
